Cutaneous T-Cell Lymphoma Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
Dallas, TX (PRWEB) April 07, 2015 -- The report “Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2015” provides comparative analysis on the therapeutic development for Cutaneous T-Cell Lymphoma. Cutaneous T-cell lymphomas (CTCLs) are a group of disorders characterized by abnormal accumulation of malignant T-cells in the skin potentially resulting in the development of rashes, plaques and tumors. Cutaneous T cell lymphoma (CTCL) has four stages of progression: patch stage, plaque stage, tumor stage, and erythroderma stage. The disease can manifest at any stage and does not necessarily go through an orderly progression. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/cutaneous-t-cell-lymphoma-pipeline-review-h1-2015-market-report.html
The report also reviews key players involved in the therapeutic development for Cutaneous T-Cell Lymphoma and special features on late-stage and discontinued projects. Companies discussed in this Cutaneous T-Cell Lymphoma – Pipeline Review, H1 2015 report include Affimed Therapeutics AG, Chipscreen Biosciences Ltd, Cornerstone Pharmaceuticals, Inc., Cyclacel Pharmaceuticals, Inc., Eisai Co., Ltd., Galderma S.A., Innate Pharma SA, Johnson & Johnson, Karyopharm Therapeutics, Inc., Kyowa Hakko Kirin Co., Ltd., MedImmune, LLC, Neumedicines Inc., Novartis AG, OncoSec Medical Inc., Onyx Pharmaceuticals, Inc., Sanofi, Soligenix, Inc., Taiwan Liposome Company, Ltd., Takeda Pharmaceutical Company Limited and TetraLogic Pharmaceuticals.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Drug Profiles mentioned in this report are A-dmDT390-bisFv, AFM-13, alemtuzumab, AMP-224, Angeloxin, bexarotene, brentuximab vedotin, carfilzomib, CIGB-128, CPI-613, CS-055, DNA IL-12, everolimus, IPH-4102, mogamulizumab, NMIL-121, quisinostat, sapacitabine, selinexor, SGX-301, SHP-141, trifarotene and vinorelbine tartrate. Order a purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=347016. (This is a premium report priced at US$2000 for a single user License.)
Featured News & Press Releases cover by this report include: Jan 07, 2015: FDA Grants Soligenix Fast Track"Designation for SGX301 for the First-Line Treatment of Cutaneous T-Cell Lymphoma 168, Dec 18, 2014: TetraLogic Announces Initiation of a Randomized Phase 2 Clinical Trial of SHAPE in Subjects With Cutaneous T-Cell Lymphoma 168, Nov 03, 2014: IPH 4102 Preclinical Data Published In Cancer Research 169, Sep 17, 2014: Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 169, Aug 27, 2014: Innate Pharma's IPH4102 Receives Orphan Drug Designation In European Union 170, Apr 08, 2014: Seattle Genetics Achieves Milestones Under Collaboration with Takeda for Achieving First Commercial Sales of ADCETRIS in Key Countries 170, Apr 07, 2014: OncoSec Medical To Relaunch Phase II Cutaneous T-Cell Lymphoma Study at Key Centers of Excellence 171, Mar 17, 2014: Approval for Additional Indication for PTCL and CTCL of Mogamulizumab 172, Jan 15, 2014: Addition of Japanese Sites for Pivotal Phase 3 Trial of Mogamulizumab in Patients with Cutaneous T-Cell Lymphoma 173 and Oct 08, 2013: OncoSec Medical Announces Positive Preliminary Safety Data in Combination Study 173.
List of Tables
Number of Products under Development for Cutaneous T-Cell Lymphoma, H1 2015 10
Number of Products under Development for Cutaneous T-Cell Lymphoma - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 12
Number of Products under Development by Companies, H1 2015 (Contd..1) 13
Number of Products under Investigation by Universities/Institutes, H1 2015 14
Comparative Analysis by Late Stage Development, H1 2015 15
Comparative Analysis by Clinical Stage Development, H1 2015 16
Comparative Analysis by Early Stage Development, H1 2015 17
Products under Development by Companies, H1 2015 18
Products under Development by Companies, H1 2015 (Contd..1) 19
Assessment by Monotherapy Products, H1 2015 41
Number of Products by Stage and Target, H1 2015 43
Number of Products by Stage and Mechanism of Action, H1 2015 45
Number of Products by Stage and Route of Administration, H1 2015 47
Number of Products by Stage and Molecule Type, H1 2015 49
Cutaneous T-Cell Lymphoma Therapeutics - Recent Pipeline Updates, H1 2015 102
Cutaneous T-Cell Lymphoma - Dormant Projects, H1 2015 164
Cutaneous T-Cell Lymphoma - Dormant Projects (Contd..1), H1 2015 165
Cutaneous T-Cell Lymphoma - Dormant Projects (Contd..2), H1 2015 166
Cutaneous T-Cell Lymphoma - Discontinued Products, H1 2015 167
Explore more reports on Pharmaceuticals industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals .
About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
Ritesh Tiwari, RnR Market Research, http://www.rnrmarketresearch.com/, +1 (888) 391-5441, [email protected]
Share this article